|
Parameters
|
SDHA
|
SDHB
|
|---|
|
Negative n = 41 (%)
|
Positive n = 680 (%)
|
P-value
|
Negative n = 24 (%)
|
Positive n = 697 (%)
|
P-value
|
|---|
|
Age (years, mean ± SD)
|
45.4 ± 10.3
|
49.9 ± 10.9
|
0.012
|
46.9 ± 9.1
|
49.7 ± 10.9
|
0.212
|
|
Histologic grade
| | |
0.062
| | |
0.044
|
|
I/II
|
33 (80.5)
|
451 (66.3)
| |
21 (87.5)
|
463 (66.4)
| |
|
III
|
8 (19.5)
|
229 (33.7)
| |
3 (12.5)
|
234 (33.6)
| |
|
ER
| | |
0.405
| | |
0.286
|
|
Negative
|
12 (29.3)
|
249 (36.6)
| |
6 (25.0)
|
255 (36.6)
| |
|
Positive
|
29 (70.7)
|
431 (63.4)
| |
18 (75.0)
|
442 (63.4)
| |
|
PR
| | |
0.748
| | |
1.000
|
|
Negative
|
21 (51.2)
|
325 (47.8)
| |
11 (45.8)
|
335 (48.1)
| |
|
Positive
|
20 (48.8)
|
355 (52.2)
| |
13 (54.2)
|
362 (51.9)
| |
|
HER-2
| | |
0.693
| | |
0.800
|
|
Negative
|
34 (82.9)
|
539 (79.3)
| |
20 (83.3)
|
553 (79.3)
| |
|
Positive
|
7 (17.1)
|
141 (20.7)
| |
4 (16.7)
|
144 (20.7)
| |
|
Tumor stage
| | |
0.750
| | |
0.213
|
|
T1
|
21 (51.2)
|
329 (48.4)
| |
15 (62.5)
|
335 (48.1)
| |
|
T2/T3
|
20 (48.8)
|
351 (51.6)
| |
9 (37.5)
|
362 (51.9)
| |
|
Nodal stage
| | |
0.625
| | |
0.529
|
|
N0
|
26 (63.4)
|
399 (58.7)
| |
16 (66.7)
|
409 (58.7)
| |
|
N1/N2/N3
|
15 (36.6)
|
281 (41.3)
| |
8 (33.3)
|
288 (41.3)
| |
|
Molecular subtypes
| | |
0.452
| | |
0.134
|
|
Luminal A
|
21 (51.2)
|
281 (41.3)
| |
15 (62.5)
|
287 (41.2)
| |
|
Luminal B
|
8 (19.5)
|
160 (23.5)
| |
3 (12.5)
|
165 (23.7)
| |
|
HER-2
|
5 (12.2)
|
64 (9.4)
| |
3 (12.5)
|
66 (9.5)
| |
|
TNBC
|
7 (17.1)
|
175 (25.7)
| |
3 (12.5)
|
179 (25.7)
| |
|
Ki-67 LI (%, mean ± SD)
|
13.0 ± 12.3
|
17.5 ± 18.7
|
0.127
|
9.9 ± 10.0
|
17.5 ± 18.6
|
0.046
|
|
Tumor recurrence
|
4 (9.8)
|
59 (8.7)
|
0.775
|
1 (4.2)
|
62 (8.9)
|
0.714
|
|
Patient death
|
4 (9.8)
|
56 (8.2)
|
0.768
|
1 (4.2)
|
59 (8.5)
|
0.713
|
- SDH succinate dehydrogenase, TNBC triple negative breast cancer.
